The majority of executives believe their boards are not sufficiently prepared to deal with the new risks related to fraud and corruption as companies return to growth, reveals the Ernst & Young 11th Global Fraud Survey, Driving Ethical Growth – New Markets, New Challenges.
More than half of approximately 2,100 business professionals (56 percent) surveyed during a Deloitte webcast about reducing fraud risks think more financial statement fraud will be uncovered this year and in 2011, as compared to the last three years.
Barbara Porco, director of program development for the Fordham University Schools of Business Administration, discusses why the trend toward reducing corporate training programs in the name of cost cutting, particularly in the financial services industry, is unwise.
Erick O. Bell, a Senior Manager at Deloitte Financial Advisory Services LLP, presents a detailed internal control checklist that outlines 5 anti-fraud strategies companies can use to deter, prevent, and detect fraud.
Thirty-five-year-old Curtis Wiltshire worked as an information and technical analyst at the Federal Reserve Bank of NY in lower Manhattan, where he had access to the personal identification information of many employees. In 2006, he stole identification information from FRB-NY and provided that to his forty-one-year-old brother Kenneth.
In this CCI featured article, Tim Lupfer and Mike Fuchs of Deloitte Consulting share their advice on how to effectively managing human capital risk, including best practices for risk management training and ingraining risk management into the corporate culture.
by Dan Hurson, senior partner in The Hurson Law Firm LLP, in Washington, D.C. The case for strict enforcement of Sarbanes-Oxley Section 304 requiring CEO payback after restatements caused by “misconduct.”
Depending on a company’s ultimate objectives, having the correct balance within the control structure is the key to a successful internal fraud investigation.
New featured article by Luis Ramos, Chief Executive Officer for The Network. As with many situations of adversity, the current economic downturn presents an opportunity for a Chief Compliance Officer (CCO) to strengthen their company’s ethics and compliance programs.
By Joel Hesch, Liberty University
The government has honed in on three primary areas where it alleges that a pharmaceutical company commits fraud. In addition, there is an emerging new area, adulterated products, where the DOJ is beginning to investigate and just may be the next huge compliance risk.
